Cargando…
ANT‐DBS in epilepsy shows no effect on selected neuropsychiatric tests
OBJECTIVES: Deep brain stimulation of the anterior thalamic nucleus (ANT‐DBS) is an established option in treatment‐resistant epilepsy and obtained FDA approval in 2018. Increased psychiatric comorbidity is well known in epilepsy. The main objective of this study was to investigate possible neuropsy...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545573/ https://www.ncbi.nlm.nih.gov/pubmed/35649713 http://dx.doi.org/10.1111/ane.13658 |
_version_ | 1784804849875943424 |
---|---|
author | Herrman, Helle Osnes, Kåre Egge, Arild Konglund, Ane Ramm‐Pettersen, Jon Dietrichs, Espen Taubøll, Erik |
author_facet | Herrman, Helle Osnes, Kåre Egge, Arild Konglund, Ane Ramm‐Pettersen, Jon Dietrichs, Espen Taubøll, Erik |
author_sort | Herrman, Helle |
collection | PubMed |
description | OBJECTIVES: Deep brain stimulation of the anterior thalamic nucleus (ANT‐DBS) is an established option in treatment‐resistant epilepsy and obtained FDA approval in 2018. Increased psychiatric comorbidity is well known in epilepsy. The main objective of this study was to investigate possible neuropsychiatric treatment‐related changes in patients receiving ANT‐DBS. MATERIALS AND METHODS: Bilateral ANT electrodes were implanted in 18 adult patients with refractory epilepsy in a randomized, double‐blinded study. Immediately after implantation, patients were randomized to stimulation ON (n = 8) or OFF (n = 10) for the first 6 months (blinded phase). During the next six months (open phase), both groups received active stimulation. Neuropsychiatric assessment was conducted before implantation (T1), at the end of the blinded period (T2), and 1 year after implantation (T3). RESULTS: Comparing preoperative status (T1) and 12 months (T3), postoperative outcome in all patients did not show significant differences between the two groups for any of the applied tests. Groupwise comparisons across the two first time points (the blinded period, representing the randomized controlled trial) showed no significant differences between the two groups in any of the neuropsychiatric parameters studied. Comparing test results after 6 months of stimulation in both groups (sum of ON group T1 to T2 and OFF group T2 to T3) did not show significant changes for any of the psychiatric assessments. CONCLUSIONS: Our results indicate that ANT‐DBS has limited effect concerning psychiatric issues. Subjective side effects were, however, reported in individual patients. |
format | Online Article Text |
id | pubmed-9545573 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95455732022-10-14 ANT‐DBS in epilepsy shows no effect on selected neuropsychiatric tests Herrman, Helle Osnes, Kåre Egge, Arild Konglund, Ane Ramm‐Pettersen, Jon Dietrichs, Espen Taubøll, Erik Acta Neurol Scand Original Articles OBJECTIVES: Deep brain stimulation of the anterior thalamic nucleus (ANT‐DBS) is an established option in treatment‐resistant epilepsy and obtained FDA approval in 2018. Increased psychiatric comorbidity is well known in epilepsy. The main objective of this study was to investigate possible neuropsychiatric treatment‐related changes in patients receiving ANT‐DBS. MATERIALS AND METHODS: Bilateral ANT electrodes were implanted in 18 adult patients with refractory epilepsy in a randomized, double‐blinded study. Immediately after implantation, patients were randomized to stimulation ON (n = 8) or OFF (n = 10) for the first 6 months (blinded phase). During the next six months (open phase), both groups received active stimulation. Neuropsychiatric assessment was conducted before implantation (T1), at the end of the blinded period (T2), and 1 year after implantation (T3). RESULTS: Comparing preoperative status (T1) and 12 months (T3), postoperative outcome in all patients did not show significant differences between the two groups for any of the applied tests. Groupwise comparisons across the two first time points (the blinded period, representing the randomized controlled trial) showed no significant differences between the two groups in any of the neuropsychiatric parameters studied. Comparing test results after 6 months of stimulation in both groups (sum of ON group T1 to T2 and OFF group T2 to T3) did not show significant changes for any of the psychiatric assessments. CONCLUSIONS: Our results indicate that ANT‐DBS has limited effect concerning psychiatric issues. Subjective side effects were, however, reported in individual patients. John Wiley and Sons Inc. 2022-06-01 2022-09 /pmc/articles/PMC9545573/ /pubmed/35649713 http://dx.doi.org/10.1111/ane.13658 Text en © 2022 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Herrman, Helle Osnes, Kåre Egge, Arild Konglund, Ane Ramm‐Pettersen, Jon Dietrichs, Espen Taubøll, Erik ANT‐DBS in epilepsy shows no effect on selected neuropsychiatric tests |
title |
ANT‐DBS in epilepsy shows no effect on selected neuropsychiatric tests |
title_full |
ANT‐DBS in epilepsy shows no effect on selected neuropsychiatric tests |
title_fullStr |
ANT‐DBS in epilepsy shows no effect on selected neuropsychiatric tests |
title_full_unstemmed |
ANT‐DBS in epilepsy shows no effect on selected neuropsychiatric tests |
title_short |
ANT‐DBS in epilepsy shows no effect on selected neuropsychiatric tests |
title_sort | ant‐dbs in epilepsy shows no effect on selected neuropsychiatric tests |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545573/ https://www.ncbi.nlm.nih.gov/pubmed/35649713 http://dx.doi.org/10.1111/ane.13658 |
work_keys_str_mv | AT herrmanhelle antdbsinepilepsyshowsnoeffectonselectedneuropsychiatrictests AT osneskare antdbsinepilepsyshowsnoeffectonselectedneuropsychiatrictests AT eggearild antdbsinepilepsyshowsnoeffectonselectedneuropsychiatrictests AT konglundane antdbsinepilepsyshowsnoeffectonselectedneuropsychiatrictests AT rammpettersenjon antdbsinepilepsyshowsnoeffectonselectedneuropsychiatrictests AT dietrichsespen antdbsinepilepsyshowsnoeffectonselectedneuropsychiatrictests AT taubøllerik antdbsinepilepsyshowsnoeffectonselectedneuropsychiatrictests |